ReviewCureus2026
The Crossroads of Neurodegeneration: Exploring the Overlap Between Alzheimer's Disease and Depression.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) and depression are two prevalent and debilitating neuropsychiatric disorders that frequently occur together and share overlapping clinical and molecular features. Understanding shared features of AD and depression is critical for delaying disease progression and improving quality of life. The objective of this narrative review is to identify recent advances in the understanding of AD and its link to depression, with a focus on identifiable biomarkers. This review explores the converging pathophysiological pathways implicated in both AD and depression, with an emphasis on oxidative stress, mitochondrial dysfunction, microglial activation, vascular impairment, and metal ion dysregulation. Specific attention is given to biomarkers of lipid peroxidation, nucleic acid damage, and protein nitration, as well as to the role of telomerase activity and ferroptosis in neuronal cell death. Additionally, we evaluate the therapeutic potential of antidepressants in modifying disease trajectory and reducing depressive symptoms in AD patients. By investigating the molecular intersections of AD and depression, this review aims to provide a comprehensive understanding of their shared pathology and highlight new avenues for targeted interventions. Our review underscores the overlapping mechanisms between AD and depression, paving the way for earlier detection, targeted therapies, closer monitoring, and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.